111 Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$726K Buy
2,412
+1,746
+262% +$527K 0.12% 167
2026
Q1
$220K Sell
666
-785
-54% -$267K 0.05% 298
2025
Q4
$577K Buy
+1,451
New +$642K 0.13% 138

Other funds holding ALNY

111 Capital's ALNY Position: Q2 2026 in Review

111 Capital increased its Alnylam Pharmaceuticals (ALNY) stake by 262% in Q2 2026, buying an estimated $527K and bringing the position to 2,412 shares worth $726K. The position accounts for 0.12% of the portfolio, ranked #167.

111 Capital first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • 111 Capital held 2,412 shares of Alnylam Pharmaceuticals worth $726K as of Q2 2026.
  • 111 Capital bought 1,746 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $527K.
  • Alnylam Pharmaceuticals made up 0.12% of 111 Capital's portfolio in Q2 2026, its #167 holding.
  • 111 Capital first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on 111 Capital's 13F filing for Q2 2026, filed 5 Aug 2026.